Abstract 4472: Discovery of potential RAF-selective back pocket as a promising biological target for BRAF inhibitors in the treatment of resistant melanoma: Design, synthesis, biological evaluation and in silico studies
(2024)
Presentation / Conference Contribution
Ammar, U., Gamal, M., Abdel-Maksoud, M., Ali, E., Mahmoud, Z., Deug, K., Jun, P., Lee, S., & Oh, C. Abstract 4472: Discovery of potential RAF-selective back pocket as a promising biological target for BRAF inhibitors in the treatment of resistant melanoma: Design, synthesis, biological evaluation and in silico studies. Presented at American Association for Cancer Research Annual Meeting 2024, San Diego, CA
The mutated BRAF kinase (V600E) is considered the key component in the MAPK signaling pathway that was reported to be significantly contributed to melanoma disease. Vemurafenib and dabrafenib are examples of drugs that were approved by FDA to treat m... Read More about Abstract 4472: Discovery of potential RAF-selective back pocket as a promising biological target for BRAF inhibitors in the treatment of resistant melanoma: Design, synthesis, biological evaluation and in silico studies.